Theflyonthewall.com is Wall Street's specialist in breaking equity news. Veteran traders build a proprietary feed of news that's faster and more relevant than any other source. Try us for free and discover for yourself.
Theflyonthewall.com is Wall Street's specialist in breaking equity news. Veteran traders build a proprietary feed of news that's faster and more relevant than any other source. Try us for free and discover for yourself.
BloggingStocks: Analyst upgrades:
Oppenheimer upgraded Momenta Pharmaceuticals (MNTA) to outperform from perform as it finds the stock attractive ahead of FDA's decision on M-enoxaparin. The firm has a $15 price target on the stock.
Wells Fargo upgraded ... Read more
Genta Inc. (OTC: GETA.OB) will host a conference call and live audio webcast to review top-line results of its AGENDA Phase 3 trial of Genasense (oblimersen sodium) Injection in patients with advanced melanoma on 10/29/09 at 8am ET. On 7/14/09, Genta announced the publication of a paper that independently confirms the link of a key biomarker to overall survival in patients with advanced melanoma. The biomarker, a tumor-derived enzyme known as lactate dehydrogenase (LDH), is measured by a widely available blood test. The Phase 3 AGENDA study has specified low-normal LDH as an enrollment criterion and the co-primary endpoints in this trial include progression-free survival (PFS) and overall survival (OS).
On 5/19/09, Genta announced that the independent Data Monitoring Board (DMB) for AGENDA notified the Company that the study passed its final futility analysis for progression-free survival (PFS). Accordingly, the Board has recommended that the study should continue to completion. On 7/13/09, Genta began trading under a new ticker (GETA.OB) after implementing a previously announced one-for-fifty reverse stock split of its common stock which reduced the number of outstanding shares from about 5.4 billion to around 108 million shares.
Neurocrine Biosciences (NASDAQ: NBIX) held a Type C meeting with FDA in August to discuss the non-menstrual pelvic pain scale proposed by the Agency and used in the Lilac Petal Study (0702). Based on this meeting, the Company modified the wording of the non-menstrual pain daily scale and launched a new clinical trial, the Daisy Petal Study (0901). This double-blind placebo-controlled clinical trial is designed to provide an assessment of this modified scale over a two month treatment period of 150 mg elagolix, followed by 20 weeks of open-label treatment.
NBIX expects to report top-line data from the Daisy Petal Study (0901) during 2Q10. The Tulip Petal Study (0703) has completed subject randomization (n=174) and treatment through Week 12 in Central Eastern Europe. This study is designed as a randomized, double-blind, placebo and active controlled trial with four treatment arms; elagolix 150 mg, elagolix 250 mg, leuprolide depot, and placebo. NBIX expects top-line data based on the first three months of placebo and active controlled treatment to be available later in 4Q09.
On 10/28/09, Cyclacel Pharma (NASDAQ: CYCC) announced top-line survival data for the primary endpoint of the Phase 2 study of sapacitabine as a treatment for elderly patients aged 70 or older with either newly diagnosed acute myeloid leukemia (AML) or AML in first relapse. The study was a three-arm randomized trial evaluating three dosing schedules of sapacitabine. The primary endpoint of 1-year survival is approximately 30% each on two out of the three schedules tested. Details of the results from this study will be presented at an upcoming medical conference. CYCC is currently working with the FDA to design a Phase 3 registration study for sapacitabine in patients with hematological malignancies.
NetEase.com, Inc. (NTES) is one of the leading providers of online gaming, advertising, web-based communication services, and a variety of interactive content in China. NetEase is currently trading at 16.8x estimated 2008 EPADR of $1.56, a discount to the industry. Rolling our valuation to fiscal 2009 EPADR estimate of $1.74, the company is trading at 15.1x, which is far below the industry average. NetEase faces intense competition in the gaming and advertising market. Delayed product launches and growing operating expenses have hurt profitability. NetEase appears to have turned the corner, posting better-than-expected revenue and earnings results in the first half of 2008. The company?s solid execution in its online games and advertising business has helped NTES grow its top and bottom line. We believe that China's online gaming and[More...]
In the world of bioscience, product development is all well and good but does little for potential investors until those products make their way through the approvals process. The closer the products get to approval, the closer an investor will be to potential profit. If an investor can find a company that is far enough [...]
WITH RESPECT TO THE US’ GDP GROWTH, THE NATIONAL BUREAU OF ECONOMIC RESEARCH SEES A SIGNIFICANT DECLINE IN ECONOMIC ACTITIVY SPREAD ACROSS THE ECONOMY, WHICH WILL LAST MORE THAN A FEW MONTHS - WSJ - According to Robert Hall, economist at Stanford University, US economic data that has been reported provide (...)
[More...]
All News |
Breaking News |
Featured Stories